Intranasal COVID 19 vaccine - BlueWillow Biologics
Alternative Names: BW-1019; Nanoemulsion adjuvanted intranasal COVID 19 vaccine - BlueWillow Biologics; S-2P-NE-01Latest Information Update: 28 Nov 2024
At a glance
- Originator BlueWillow Biologics
- Class COVID-19 vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in USA (Intranasal)
- 02 Mar 2022 Preclinical trials in COVID-2019 infections (Prevention) in USA (IM)
- 02 Mar 2022 Pharmacodynamics data from a preclinical trial in COVID-2019 infections released by BlueWillow Biologics and Medigen Vaccine Biologics